Controlled Delivery of Nitric Oxide for Cancer Therapy

• Published in: Pharmaceutical nanotechnology Vol. 7; no. 4; p. 279
• Main Authors: Alimoradi, Houman, Greish, Khaled, Gamble, Allan B, Giles, Gregory I
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 2019
• Subjects: Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Drug Carriers; Drug Delivery Systems; Humans; Neoplasms - drug therapy; Nitric Oxide - chemistry; Nitric Oxide - pharmacology; Nitric Oxide - therapeutic use; Nitric Oxide Donors - chemistry; Nitric Oxide Donors - pharmacology; Nitric Oxide Donors - therapeutic use; nitric oxide; nanoparticles; nitric oxide donors; Cancer therapy; controlled delivery; nitric oxide releasing biomaterials
• ISSN: 2211-7393
• DOI: 10.2174/2211738507666190429111306

Nitric oxide (NO) is a short-lived, endogenously produced, signaling molecule which plays multiple roles in mammalian physiology. Underproduction of NO is associated with several pathological processes; hence a broad range of NO donors have emerged as potential therapeutics for cardiovascular and respiratory disorders, wound healing, the immune response to infection, and cancer. However, short half-lives, chemical reactivity, rapid systemic clearance, and cytotoxicity have hindered the clinical development of most low molecular weight NO donors. Hence, for controlled NO delivery, there has been extensive effort to design novel NO-releasing biomaterials for tumor targeting. This review covers the effects of NO in cancer biology, NO releasing moieties which can be used for NO delivery, and current advances in the design of NO releasing biomaterials focusing on their applications for tumor therapy.